Abstract: A composition containing titanium and iron compounds, in particular decomposition residue that accumulates as a production residue after the sulphate process during the production of titanium dioxide, is used as an adsorbing agent for inorganic and organic compounds, for example compounds containing phosphorus, arsenic, antimony, sulphur, selenium, tellurium, the cyano group or heavy metal. Toxic substances and pollutants may be removed from a fluid using the adsorbing agent.

Abstract: SOx removal equipment for reducing sulfur oxides from flue gas from a boiler, a cooler which is provided on the downstream side of the SOx removal equipment, for reducing the sulfur oxides from the flue gas and for decreasing a gas temperature, CO2 recovery equipment which includes an absorber for bringing CO2 in the flue gas into contact with a CO2 absorption liquid so as to be reduced and a regenerator for causing the CO2 absorption liquid to emit CO2 so as to recover CO2 and regenerate the CO2 absorption liquid, and dissolved salt spraying equipment for reducing a mist generation material which is a generation source of mist that is generated in the absorber of the CO2 recovery equipment before introducing the flue gas to the CO2 recovery equipment, are included.

Abstract: Aspects of the invention relate to a method of treating a gas stream generated by a motorcycle, the method comprising: contacting a gas stream containing hydrocarbons, carbon monoxide and nitrogen oxides and generated by a motorcycle under both rich and lean engine operating conditions with a base metal catalyst composition, thereby removing at least a part of the hydrocarbons, carbon monoxide and nitrogen oxides in gas stream. The base metal catalyst composition comprises a support including at least 10% by weight of reducible ceria, and about 3 to about 7 wt % MnO and about 8 to about 22 wt % CuO on the reducible ceria support. The base metal catalyst composition is effective to promote a steam reforming reaction of hydrocarbons and a water gas shift reaction to provide H2 as a reductant to abate NOx.

Abstract: An exhaust system 10 for a vehicular lean-burn internal combustion engine comprises: (a) a first substrate monolith 6 comprising a SCR catalyst; (b) at least one second substrate monolith 4 comprising a catalytic washcoat coating comprising at least one platinum group metal (PGM) disposed upstream of the first substrate monolith; and (c) a third substrate monolith 2 disposed between the first substrate monolith and the or each second substrate monolith, wherein at least one PGM on the or each second substrate monolith 4 is liable to volatilise when the or each second substrate monolith 4 is exposed to relatively extreme conditions including relatively high temperatures, and wherein the third substrate monolith 2 comprises a washcoat coating comprising at least one metal oxide for trapping volatilised PGM.

Abstract: A system for reducing NOx in a flue gas stream, including an absorption element, a first inlet in fluid communication with the chamber configured to deliver a pressurized flue gas to the chamber, and a second inlet in fluid communication with the chamber configured to deliver an absorbing additive to the chamber. An outlet is in fluid communication with the chamber to exhaust from the chamber flue gas that has contacted the absorbing additive. A method for reducing NOx in a flue gas including the steps of: providing a flue gas in a chamber of an absorption element, providing an absorbing additive so that it contacts at least a portion of the flue gas, and exhausting at least a portion of the flue gas from the chamber.

Abstract: Disclosed is a catalyst composition for reducing NOx through two steps including reacting NOx with H2 thus producing ammonia which is then reacted with NOx, instead of direct NOx reduction by H2, and a method of reducing NOx using the catalyst composition.

Abstract: The present invention relates to a method for processing a sulfur-containing gas and a hydrogenation catalyst used therefor. The method comprises introducing the sulfur-containing gas into the tail gas hydrogenation unit of a sulfur recovery device, processing it with the hydrogenation catalyst of the present invention, and absorbing the hydrogenated tail gas with a solvent. The hydrogenation catalyst comprises from 0.5 to 3 wt. % of an active component nickel oxide, from 1 to 4 wt. % of an active component cobalt oxide, from 8 to 20 wt. % of an active component molybdenum oxide or tungsten oxide, from 1 to 5 wt. % of a deoxidation auxiliary agent, from 10 to 40 wt. % of TiO2, the balance being ?-Al2O3, based on the weight of the catalyst.

Abstract: In a purifying method for metal grade silicon, metal grade silicon with a silicon concentration not less than 98 wt % and not more than 99.9 wt % is prepared. The metal grade silicon contains aluminum not less than 1000 ppm and not more than 10000 ppm by weight. The metal grade silicon is heated at a temperature not less than 1500° C. and not more than 1600° C. in an inert atmosphere under pressure not less than 100 Pa and not more than 1000 Pa, and maintained at the temperature in the atmosphere for a predetermined period.

Abstract: The present invention relates to a method for making a twisted carbon nanotube wire. Two opposite ends of the at least one carbon nanotube film is clamped by two clamps. The two clamps is pulled along two reversed directions to stretch the at least one carbon nanotube film. The at least one carbon nanotube film is twisted by rotating the two clamps while the at least one carbon nanotube film is in a straightening state.

Abstract: The present invention relates to compositions and methods for producing hydrogen from water involving reacting metal particles with water in the presence of an effective amount of activator. In particular the invention pertains to compositions and methods for producing hydrogen upon reaction of metal particles selected from the group consisting of aluminum (Al), magnesium (Mg), boron (B), silicon (Si), iron (Fe), and zinc (Zn) with water, in the presence of an effective amount of an activator catalyst, wherein the activator is selected from the group consisting of: alkali metals, earth alkali metals, hydrides of alkali metals, hydrides of earth alkali metals, hydroxides of alkali metals, and hydroxides of earth alkali metals.

Abstract: Methods and compositions for effectively lowering the carbon-14 content, particularly of DNA and histones in vertebrates, especially humans, to significantly below normal background levels and thereby reduce chromosomal damage using nutritional or dietary supplements based on low radiocarbon DNA, amino acid and histone precursors, further preferably including those which contribute the largest share of histone carbon atoms. Administration of the supplements during the earliest and/or most active growth stages of life is particularly beneficial. Particularly useful supplements are prepared by combining low radiocarbon precursor compounds with ordinary supplement or dietary components that exhibit substantially normal background radiocarbon concentrations.

Abstract: A sprayable polymeric foam hemostat for both compressible and non-compressible (intracavitary) acute wounds is disclosed. The foam comprises hydrophobically-modified polymers, such as hm-chitosan, or other amphiphilic polymers that anchor themselves within the membrane of cells in the vicinity of the wound. By rapidly expanding upon being released from a canister pressurized with liquefied gas propellant, the foam is able to enter injured body cavities and staunch bleeding. The seal created is strong enough to substantially prevent the loss of blood from these cavities. Hydrophobically-modified polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The amphiphilic polymers form solid gel networks with blood cells to create a physical clotting mechanism that prevent loss of blood.

Abstract: The cancer-imaging agent and method of radioimaging relates to the use of a radioimaging agent for the imaging increased choline uptake to detect cancerous tissue. The radioimaging agent includes choline or a pharmaceutically acceptable salt thereof labeled with technetium-99m. Preferably, the radioimaging agent is [methyl]-choline chloride labeled with 99mTcO4, which carries technetium-99m. In use, a patient is administered an effective amount of the radioimaging agent by injection and then scanned with a radioimaging device. The radioimaging agent is used to image select soft tissues in the patient, such as the liver or gallbladder, the upper abdominal organs, or the like, and to detect increased choline uptake. Choline is known to accumulate in cancerous cells. Thus, the radioimaging agent is particularly effective in the detection of potentially cancerous tissues.

Abstract: Methods, devices and compositions for treatment of severe and uncontrolled asthma are provided by which high amounts of an inhaled corticosteroid are directed to the small airways of the lower lungs. The invention provides for a substantial decrease in the dose of concurrently administered oral corticosteroids. A particular advantage of the invention is the significant reduction in corticosteroid-related adverse effects.

Abstract: In a personal care daily practice, common human malodor in breath can be treated and eliminated or substantially reduced through the use of a treatment comestible, lozenge, chewing gum or scraper prepared by combining a hardenable natural or artificial sweetener or gum base with an amount of activated carbon effective in reducing such malodors.

Abstract: This invention provides, inter alia, commensal organisms engineered to express antibody fragments, which inhibit sperm motility or fertilization and compositions comprising the same. The present invention provides for the use of the engineered commensal organisms or compositions comprising the same as effective contraceptive means in females.

Abstract: The present invention relates to influenza vaccine formulations and accelerating primary vaccination regimes for immunizing against influenza disease, their use in medicine, in particular their use in promoting effective immune responses to various antigens, and to methods of preparation. In particular, the invention relates to two-doses accelerated pandemic or seasonal pandemic primary immunization regimes with influenza immunogenic compositions comprising an influenza virus or antigenic preparation thereof in combination with an oil-in-water emulsion adjuvant, and to accelerated immunization regimes.

Abstract: The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is administered to the therapy-resistant hyperproliferative cells. The present invention thus provides immunotherapies for treating therapy-resistant hyperproliferative disease by attenuating the natural immune system's CTL response against hyperproliferative cells or overexpressing mutant p53 antigens, for example.

Abstract: The invention relates to a composition comprising an effective amount of at least one of the strains selected from the group consisting of Lactobacillus plantarum CECT 7527, Lactobacillus plantarum CECT 7528, and Lactobacillus plantarum CECT 7529, These new strains have good probiotic features and are useful for the prevention and/or the treatment of cardiovascular disorders.

Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.

Abstract: Extract fractions of Dioscorea sp. and methods of preparing the extract fractions are disclosed. The extract fractions enhance the proliferation and differentiation of bone marrow cells. Also described are a method for treatment of osteoporosis and a method for alleviation of side effects caused by chemotherapy by using the extract fractions of Dioscorea sp.

Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.

Abstract: The present disclosure relates to an antibody or an epitope-binding fragment thereof that specifically binds to an EphA2 receptor. It further relates to a conjugate comprising a cytotoxic agent which is covalently bound to the antibody and a method for preparing such a conjugate.

Abstract: The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides immunogenic nanoemulsion compositions and methods of using the same for the induction of immune responses (e.g., innate and/or adaptive immune responses (e.g., for generation of host immunity against a bacterial species of the genus Streptococcus (e.g., Streptococcus pneumoniae))). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

Abstract: The present invention provides a formulation that prevents virulent Mycoplasma galHsepticum infection in birds of the order GaIHf ormes. The formulation comprises live Mycoplasma galHsepticum strain K5831 or derivatives thereof in a pharmaceutically acceptable carrier. A vaccine that prevents virulent Mycoplasma galHsepticum infection in birds of the order Galliformes is also presented. Methods for administering the formulation and vaccine are also presented.

Abstract: This invention relates to novel compositions and methods of use by which the compositions of this invention are applied topically to one or more body parts of at least two individuals who bring said body parts into contact with the other individual and, when said body parts come into contact with each other, permit the formulations to interact and thereby achieve an unexpected sensation to each individual.

Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.

Abstract: Process for the preparation of a an inverse latex including from 20% to 70% by weight and preferably from 25% to 50% by weight of a branched or crosslinked polyelectrolyte, characterized in that the polyelectrolyte is a copolymer of 2-acrylamido-2-methylpropanesulfonic acid partially or totally salified with acrylamide and optionally one or more monomers chosen from monomers containing a partially or totally salified weak acid function and/or from neutral monomers other than acrylamide, the production process including the control of the pH in the initial aqueous phase; Cosmetic, dermopharmaceutical or pharmaceutical composition including the inverse latex directly obtained by the process.

Abstract: The invention relates to process for making highly concentrated, spherical biopolymer gel particle suspensions comprising particles of defined particle diameter (e.g., range of 1 to 50?) utilizing high internal phase emulsion as an intermediate.

Abstract: Bisurea gelling agents that impart a number of unexpected benefits within various gelled formulations and exhibit great versatility in terms of gelling capabilities for many types of solvents are provided. Such gelling agents should include pendant groups, such as sterically hindering alkyl groups attached to polyoxyalkylenated moieties that allow the gelling agent to be compatible with the target liquid system at elevated temperatures, while controlling and/or limiting the network formation and strength during the cooling cycle. Alternatively, novel gelling agents having two urea groups but that are asymmetrical in configuration have been produced in order to provide the same control in temperature, compatibility, and efficiency. Final gelled formulations, such as antiperspirant sticks and other like consumer items, are provided as well within this invention.

Abstract: A polymer comprising a phosphoryl choline moiety(ies), a composition comprising the polymer and optionally a bioactive agent, an implantable device such as a DES or a non-implantable device such as an angioplasty balloon comprising thereon a coating comprising the polymer and optionally a bioactive agent, and a method of using the device for the treatment of a disorder in a human being are provided.

Abstract: A method, device, and system for easier, consistent, and comfortable delivery of therapeutic agents to the front of the eye.

Abstract: The present invention provides lipase inhibitors containing dimers of flavan-3-ols derived from teas as well as foods and beverages and medicines containing said inhibitors. More specifically, the present invention provides lipase inhibitors containing at least one of assamicains represented by the formula: wherein G represents a galloyl group; theasinensins represented by the formula: wherein R1 represents G or H, and R2 represents G; and theaflavins represented by the formula: wherein R1 and R2 independently represent G or H; as well as foods and beverages and medicines containing said lipase inhibitors.

Abstract: This invention is directed to compositions for animal consumption (including foods, treats, etc.), particularly compositions that tend to improve kidney function, and particularly compositions that comprise enhanced antioxidants and reduced quantities of protein and/or phosphorus. This invention also is directed generally to methods for using such compositions.

Abstract: Washing with conventional filmy soaps cannot bring about clean detergent effect because of the remaining sliminess due to the ingredient essential for forming soap into films. Further, when moisture adheres to conventional filmy compositions, the water-soluble polymer or other ingredients contained in the compositions dissolve in the moisture to cause the blocking of filmy compositions, which makes it impossible to take out the filmy compositions one by one. Detergent effect without sliminess and the antiblocking of filmy compositions can be attained by incorporating a granular component into a filmy composition containing a water-soluble polymer. The filmy compositions of the invention are used as filmy facial masks, whitening masks, sheet soap, cleansing sheets, sheet shampoos, sheet rinses, sheet bath additives, and so on.

Abstract: This invention is directed to advanced hemorrhage control wound dressings, and methods of using and producing same. The subject wound dressing is constructed from a non-mammalian material for control of severe 5 bleeding. The wound dressing for controlling severe bleeding is formed of a biomaterial comprising chitosan, a hydrophilic polymer, a polyacrylic polymer or a combination thereof, The kind of severe, life-threatening bleeding contemplated by this invention is typically of the type not capable of being stanched when a conventional gauze wound dressing is applied with conventional 10 pressure to the subject wound. The wound dressing being capable of substantially stanching the flow of the severe life-threatening bleeding from the wound by adhering to the wound site, to seal the wound, to accelerate blood clot formation at the wound site, to reinforce clot formation at the wound site and prevent bleed out from the wound site, and to substantially prohibit the flow of 15 blood out of the wound site.

Abstract: The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.

Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Abstract: This invention relates generally to the treatment of cathepsin or dynamin mediated diseases, such as proteinuria, cancer, and cognitive disease and related products. Diagnostic and other assays are also provided, as well as methods for podocyte cell gene transfer.

Abstract: A capsule for a powder has a body which is provided with an internal chamber to hold the powder and first and second openings to an exterior environment. The body is adapted to be displaced from a filling state, in which the first and second openings are placed in fluid communication with one another through the internal chamber thereby enabling an airflow to be created through the body from the second opening to the first opening which is able to entrain powder in the exterior environment into the internal chamber for filling thereof, to a sealing state in which the internal chamber is sealed from the exterior environment so as to retain the powder held therein.

Abstract: Compositions and methods for the treatment of pain in a mammal are described. More specifically, a dosage form designed for release of acetaminophen and an opioid is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time.

Abstract: Provided is a slow-release delivery vehicle for delivering at least one active ingredient into a film coating, comprising a population of stable, homogeneously-dispersed, porous polymeric or co-polymeric beads having a network of pores, wherein the at least one active ingredient is held within the bead particles and within the network of pores and slowly released by internal flow, and wherein the network of pores is substantially non-collapsible upon removal of the active ingredient. The porous co-polymer bead preparation comprises a continuous aqueous phase solution containing a monomeric mixture of at least one polyvinylaromatic monomer and at least one porogen forming a network that comprising (i) macropores; (ii) mesopores; (iii) micropores; and (iv) gel porosity. Also provided are methods of preparing the porous co-polymer bead preparation; and for its use as a slow-release delivery vehicle.

Abstract: A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described.

Abstract: A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.

Abstract: Provided are a delivery system that is useful in delivering a double-stranded ribonucleic acid that functions in gene silencing in glomeruli, particularly in mesangial cells and the like, to the tissue or cells, and the like. A polyion complex in the form of a non-polymeric micelle consisting of a double-stranded ribonucleic acid and a block copolymer represented by the formula (I) or (II) below, which are electrostatically bound together, wherein the polyion complex has an average particle diameter of less than 100 nm as measured by a dynamic light scattering measuring method: wherein each symbol is as defined in the specification.

Abstract: A method of preparing a pharmaceutical formulation comprises providing a solution comprising a first solvent, a second solvent, an active agent, and an excipient. The second solvent is less polar than the first solvent and the excipient is more soluble in water than the active agent. The first and second solvents are removed from the solution to produce particles comprising the active agent and the excipient. In one version, the excipient comprises an amino acid and/or a phospholipid. A pharmaceutical formulation made by a version of the invention comprises particles comprising an active agent and an excipient which at least partially encapsulates the active agent, wherein the excipient is more soluble in water than the active agent.

Abstract: A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells. In one embodiment, the method is administered in combination with localized internal ionizing radiation therapy.

Abstract: Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.

Abstract: The present invention generally relates to compositions and methods for transdermal drug delivery. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction, treating wounds, or causing or promoting hair growth. For example, in one aspect, the present invention is generally directed to compositions for delivery of nitric oxide, transdermally and/or to a mucosal surface. The composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the penis, vulva, or other suitable portion of the skin. The composition can also be applied to a mucosal surface in some instances.

Abstract: This invention discloses composition and manufacturing processes of a toxicity free botanical drug formulation for curative treatment of chronic diseases. It is manufactured from plants Crinum asiaticum and Crocus sativus. This drug was administered to human volunteers by oral and intranasal routes in effective amount for an effective time period. Effective amount and effective time of administration varies from one human volunteer to another depending upon age, body weight, length of disease, severity of disease, type of the disease. In vitro experiments show that this botanical drug causes proliferation and differentiation of stem cells.